Pub. Date : 2022 Mar
PMID : 35395919
9 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In the present study, we established a population pharmacokinetic model to explore the effect of combined use of Wuzhi capsules/echinocandins and the patients" biochemical parameters such as hematocrit on blood concentrations and target doses of tacrolimus in renal transplant patients with different CYP3A5 genotypes. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 2 | CYP3A5 genotypes and co-administration of Wuzhi capsules, as well as time after renal transplantation and hematocrit, were important factors affecting the clearance of tacrolimus. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 3 | The Monte Carlo simulation indicated the following recommended doses of tacrolimus alone: 0.14 mg kg-1 d-1 for genotype CYP3A5*1*1, 0.12 mg kg-1 d-1 for CYP3A5*1*3, and 0.10 mg kg-1 d-1 for CYP3A5*3*3. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 4 | The Monte Carlo simulation indicated the following recommended doses of tacrolimus alone: 0.14 mg kg-1 d-1 for genotype CYP3A5*1*1, 0.12 mg kg-1 d-1 for CYP3A5*1*3, and 0.10 mg kg-1 d-1 for CYP3A5*3*3. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 5 | The Monte Carlo simulation indicated the following recommended doses of tacrolimus alone: 0.14 mg kg-1 d-1 for genotype CYP3A5*1*1, 0.12 mg kg-1 d-1 for CYP3A5*1*3, and 0.10 mg kg-1 d-1 for CYP3A5*3*3. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 6 | For patients receiving the combination with Wuzhi capsules, the recommended doses of tacrolimus were 0.10 mg kg-1 d-1 for CYP3A5*1*1, 0.08 mg kg-1 d-1 for CYP3A5*1*3, and 0.06 mg kg-1 d-1 for CYP3A5*3*3 genotypes. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 7 | For patients receiving the combination with Wuzhi capsules, the recommended doses of tacrolimus were 0.10 mg kg-1 d-1 for CYP3A5*1*1, 0.08 mg kg-1 d-1 for CYP3A5*1*3, and 0.06 mg kg-1 d-1 for CYP3A5*3*3 genotypes. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 8 | For patients receiving the combination with Wuzhi capsules, the recommended doses of tacrolimus were 0.10 mg kg-1 d-1 for CYP3A5*1*1, 0.08 mg kg-1 d-1 for CYP3A5*1*3, and 0.06 mg kg-1 d-1 for CYP3A5*3*3 genotypes. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |
| 9 | For early kidney transplant recipients receiving tacrolimus treatment, not only body weight, but also CYP3A5 genotypes and drugs used in combination should be considered when determining the target dose of tacrolimus. | Tacrolimus | cytochrome P450 family 3 subfamily A member 5 | Homo sapiens |